Výsledky studie SAVOR-TIMI 53 pohledem kardiologa
| Title in English | Results of SAVOR-TIMI 53 from the point of view of a cardiologist |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | saxagliptin; hypoglycaemia; pancreatitis; myocardial infarction; cardiac failure |
| Description | Type 2 diabetes mellitus is a severe condition with continually growing incidence rates throughout developed countries. In the Czech Republic, approximately 8% of the general population are affected, with about 90% of them being patients with type 2 diabetes. Generally, treatment of diabetes aims at reducing patient morbidity and morta¬lity rates. Current treatments of type 2 diabetes are effective, but far from ideal. This ideal is perhaps best approximated with incretin-based therapy, undoubtedly a significant qualitati¬ve progress. Incretin hormones, currently including GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory polypeptide), have been called biochemical substances with polypeptide nature. Incretin hormones, i.e. both GLP-1 and GIP, undergo enzymatic degradation in the bloodstream with dipeptidyl peptidase-4 (DPP4) within few minutes. The mechanism of action underlying the effect of gliptins is DPP-4 inhibition. Saxagliptin Assessment of Vascular Outcomes Recorded in patients with Type 2 Diabetes Mellitus - Thrombolysis in Myocardial Infarction (SAVOR-TIMI 53 Study) involved 788 centres in 26 countries on 6 continents, including the Czech Republic. The study randomized 16,492 patients, mean age 65 ± 8.6 years, with mean diabetes duration 11.9 ± 8.9 years. The primary outcome measure (cardiovascular death, non-fatal myocardial infarction and nonfatal stroke) was observed in 7.3% (613) patients treated with saxagliptin and 7.2% (609) patients receiving placebo (HR: 1.00; p < 0.001 for nonmferiorty). From the viewpoint of diabetes mellitus treatment, 36.2% of patients receiving saxagliptin had glycated haemoglobin values less than 7%, but only 27.9% of those in the placebo group (p < 0.001). No increased rates of occurrence of pancreatitis were observed. |